Healthcare
Eli Lilly cuts price of weight-loss drug Zepbound for self-paying patients
The drug company is calling on insurers and federal programs to include coverage of obesity as a chronic disease.
Phrase
Drug zepbound
No market stories in the last 7 days. The latest coverage is below.
- 7-day mood
- —Not enough data
- Stories, 7 days
- 0
- Last 24 hours
- 0no baseline yet
- Sources
- 3in the latest 3
Mood and coverage · last 7 days
Market chart- Drug zepbound · 6-hour average
- Hourly reading
- Stories per hour
No scored stories in the last 7 days.
View as table
| Day | Mood | Stories |
|---|---|---|
| Sun, Oct 11 | — | 0 |
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
Latest on Drug zepbound
Newest firstHealthcare
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
Healthcare
FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage
The decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.
